Advertisement

Leucovorin, Cisplatin, and 5-Fluorouracil for Advanced Esophageal Cancer

  • Toshiro Konishi
  • Toru Hirata
  • Mamoru Hiraishi
  • Ken-Ichi Mafune
  • Takeshi Miyama
  • Kiyoshi Mori
  • Haruhiro Nishina
  • Yasuo Idezuki

Abstract

Biochemical modulation involves the use of one drug (modulating agent; modulator) to change the pharmacokinetics and/or pharmacodynamics of a cytotoxic agent (effector), in a way that the therapeutic index of the effector is enhanced [1]. The modulator is often also a cytotoxic agent, but a non-cytotoxic agent like leucovorin is sometimes used as well. The modulating agent improves selectivity or sensitivity of an effector and decreases its toxicity to normal cells via a biochemical or metabolical mechanism. Currently, several biochemical modulations such as the sequential methotrexate (MTX)/5-fluorouracil (5-FU), leucovorin (LV)/5-FU, and cisplatin (CDDP)/5-FU have been evaluated clinically in terms of their efficacy for alimentary tract malignancies.

Keywords

Esophageal Cancer Squamous Cell Cancer Thoracic Esophagus Modulate Agent Advanced Esophageal Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Howell SB (1986) Biochemical modulation: Current status and considerations for the future. In: Kimura K, Yamada K, Krakoff IH, Carter SK (eds) Cancer Chemotherapy—challenges for the future. Excerpta Medica, pp 108–116Google Scholar
  2. 2.
    Scanlon KJ, Newman EM, Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923–8925PubMedCrossRefGoogle Scholar
  3. 3.
    O’Dwyer PJ, Cornfeld MJ, Peter R, Comis RL (1990) Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination. Cancer Chemother Pharmacol 27: 131–134PubMedCrossRefGoogle Scholar
  4. 4.
    Vokes EE, Choi KE, Schilsky RL, Moran WJ, Guarnieri CM, Weichselbaum RR, Panje WR (1988) Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 6: 618–626PubMedGoogle Scholar
  5. 5.
    Clark J, Dreyfuss A, Norris C, Busse P, Miller D, Lucarini J, Andersen J, Casey D, Frei E (1990) Continuous infusion cisplatin, 5-FU and high-dose leucovorin (PEL): favorable early results as induction therapy for squamous cell carcinoma of the head and neck. Proc ASCO 9: 172Google Scholar
  6. 6.
    Browman GP, Archibald SD, Young JEM, Hryniuk WM, Russell R, Kiehl K, Levine MN (1983) Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. J Clin Oncol 1: 787–792PubMedGoogle Scholar
  7. 7.
    Hayashi K, Ide H, Shinoda M, Fukushima M (1992) Phase II study of cisplatin (CDDP) plus 5-fluorouracil (5-FU) and leucovorin ( LCV) for squamous cell carcinoma of the esophagus. Proc ASCO 11: 178Google Scholar

Copyright information

© Springer-Verlag Tokyo 1993

Authors and Affiliations

  • Toshiro Konishi
  • Toru Hirata
  • Mamoru Hiraishi
  • Ken-Ichi Mafune
  • Takeshi Miyama
  • Kiyoshi Mori
  • Haruhiro Nishina
  • Yasuo Idezuki
    • 1
  1. 1.The Second Department of Surgery, Faculty of MedicineUniversity of TokyoBunkyo-ku, Tokyo, 113Japan

Personalised recommendations